Kemble George 4

Accession 0001104659-23-082726

CIK 0001400118other

View on SEC.gov Company Profile

Filed

Jul 19, 8:00 PM ET

Accepted

Jul 20, 4:17 PM ET

Size

38.6 KB

Accession

0001104659-23-082726

Insider Transaction Report

Form 4

Period: 2023-07-18

Sagimet Biosciences Inc.SGMT

Kemble George

DirectorExecutive Chairman

Transactions

Award
Stock Option (Right to Buy)
2023-07-18+3,179→ 3,179 total
Exercise: $11.13Exp: 2024-03-12→ Series A Common Stock (3,179 underlying)
Award
Stock Option (Right to Buy)
2023-07-18+367,824→ 367,824 total
Exercise: $6.36Exp: 2029-04-27→ Series A Common Stock (367,824 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−5,630→ 0 total
Exercise: $0.79Exp: 2023-09-26→ Common Stock (5,630 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−7,147→ 0 total
Exercise: $23.05Exp: 2024-12-16→ Common Stock (7,147 underlying)
Award
Stock Option (Right to Buy)
2023-07-18+7,147→ 7,147 total
Exercise: $23.05Exp: 2024-12-16→ Series A Common Stock (7,147 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−26,352→ 0 total
Exercise: $19.87Exp: 2025-10-12→ Common Stock (26,352 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−3,179→ 0 total
Exercise: $11.13Exp: 2024-03-12→ Common Stock (3,179 underlying)
Award
Stock Option (Right to Buy)
2023-07-18+5,630→ 5,630 total
Exercise: $0.79Exp: 2023-09-26→ Series A Common Stock (5,630 underlying)
Award
Stock Option (Right to Buy)
2023-07-18+26,352→ 26,352 total
Exercise: $19.87Exp: 2025-10-12→ Series A Common Stock (26,352 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−526,332→ 0 total
Exercise: $6.36Exp: 2031-01-26→ Common Stock (526,332 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−367,824→ 0 total
Exercise: $6.36Exp: 2029-04-27→ Common Stock (367,824 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−46,432→ 0 total
Exercise: $6.36Exp: 2029-04-27→ Common Stock (46,432 underlying)
Award
Stock Option (Right to Buy)
2023-07-18+46,432→ 46,432 total
Exercise: $6.36Exp: 2029-04-27→ Series A Common Stock (46,432 underlying)
Award
Stock Option (Right to Buy)
2023-07-18+526,332→ 526,332 total
Exercise: $6.36Exp: 2031-01-26→ Series A Common Stock (526,332 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−21,173→ 0 total
Exercise: $7.15Exp: 2032-10-16→ Common Stock (21,173 underlying)
Award
Stock Option (Right to Buy)
2023-07-18+21,173→ 21,173 total
Exercise: $7.15Exp: 2032-10-16→ Series A Common Stock (21,173 underlying)

Footnotes (4)

[F1]Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
[F2]This option is fully vested and exercisable as of the date hereof.
[F3]The shares underlying this option vest and become exercisable in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date.
[F4]25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Documents

1 file

4
tm2321276-16_4seq1.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

Sagimet Biosciences Inc.

CIK 0001400118

→

Entity typeother

Related Parties

filerCIK 0001858176

Filing Metadata

Form type: 4
Filed: Jul 19, 8:00 PM ET
Accepted: Jul 20, 4:17 PM ET
Size: 38.6 KB

View on SEC.gov